Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.
January 28, 2015
New Approach to Delay Alzheimer’s Dementia Onset to Be Tested in Phase-3 Clinical Trial
AGB101 could be the first drug to modify progression of amnestic mild cognitive impairment (aMCI) in patients at a high-risk for progressing to Alzheimer’s dementia
